title: Transient vision loss after ocriplasmin injection.
abstract: OBJECTIVE
  Transient vision loss is a poorly understood complication of ocriplasmin injection.
  
  
  METHODS
  The authors performed a retrospective medical records review of consecutive patients who received ocriplasmin for the treatment of vitreomacular adhesion at The George Washington University Department of Ophthalmology and the Virginia Retinal Center from January 1, 2013, to March 1, 2014, and who had at least 28 days of follow-up. Ellipsoid zone loss on optical coherence tomography was analyzed using the National Institutes of Health's Medical Imaging, Processing, Analysis, and Visualization (MIPAV) software.
  
  
  RESULTS
  Ten patients received ocriplasmin injection. Three of the 10 patients (30%) had release of vitreomacular adhesion, and 8 of the 10 (80%) experienced vision loss within the first month. Average baseline visual acuity was 66 Early Treatment Diabetic Retinopathy Study letters. Average visual acuity at Weeks 1, 2, 3, and 4 was 62, 43, 57, and 56 Early Treatment Diabetic Retinopathy Study letters, respectively. Average final visual acuity was 58 Early Treatment Diabetic Retinopathy Study letters. Ellipsoid loss occurred in 5 patients and reached a nadir (-36.9% decrease from baseline) 2 weeks later.
  
  
  CONCLUSIONS
  Vision loss after ocriplasmin occurred in the majority of patients and was correlated with loss of the ellipsoid layer on optical coherence tomography. More data are needed to analyze this side effect.
authors.affiliation: Department of Ophthalmology, The George Washington University, Washington, District of Columbia.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Reiss
authors.forename: Lindsay
authors.initials: L
authors.lastname: Smithen
authors.forename: Sam
authors.initials: S
authors.lastname: Mansour
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001766:Blindness / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D005341:Fibrinolysin / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000009:adverse effects*; D012164:Retinal Diseases / Q000188:drug therapy*; D012189:Retrospective Studies; D000267:Tissue Adhesions / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D014792:Visual Acuity; D014822:Vitreous Body / Q000187:drug effects*
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin